Skip to content

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

NASH

NASH, PUBLICATIONS

Denifanstat, a fatty acid synthase inhibitor, achieved significant clinical improvement in moderate-to-severe acne vulgaris: a review of mechanistic and clinical data

By charlie maddox / 10/2026

2026 Fall Clinical Dermatology Conference

NASH, PUBLICATIONS

Denifanstat for Moderate-to-Severe Acne Vulgaris: Results from an Open-label, Multicenter, Phase III Extension Study

By charlie maddox / 10/2026

European Academy of Dermatology and Venereology (EADV) Congress 2026

NASH, PUBLICATIONS

Transcriptomic analysis revealed distinct mechanisms underlying the synergistic effect of a fatty acid synthase (FASN) inhibitor and resmetirom combination in LDL receptor knockout MASH mice

By charlie maddox / 05/2026

EASL International Liver Congress

NASH, PUBLICATIONS

Denifanstat and resmetirom combination therapy rapidly decreased atherogenic lipids in healthy adults in Phase 1 open-label trial

By charlie maddox / 05/2026

EASL International Liver Congress

NASH, PUBLICATIONS

Fatty acid synthase (FASN) inhibitors decreased sebum lipids in human sebocytes via inhibition of de novo lipogenesis, supporting FASN as a target for acne treatment

By charlie maddox / 05/2026

Society for Investigative Dermatology

NASH, PUBLICATIONS

Reduction of plasma glycine- and taurine-conjugated bile acids correlated with histological improvements in denifanstat-treated MASH patients in Phase 2b FASCINATE-2 trial

By charlie maddox / 04/2026

Keystone Symposia

NASH, PUBLICATIONS

Reduction of plasma glycine- and taurine-conjugated bile acids correlated with histological improvements in denifanstat-treated MASH patients in Phase 2b FASCINATE-2 trial

By charlie maddox / 04/2026

Keystone Symposia

NASH, PUBLICATIONS

Denifanstat elicited a significant ≥ 2-stage improvement in fibrosis in F3 MASH patients, and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients: secondary analysis of the phase 2b FASCINATE-2 trial

By charlie maddox / 01/2026

MASH TAG

NASH, PUBLICATIONS

Spatial Computational Histology Stratified Denifanstat Fibrosis Responders in the Phase 2b FASCINATE-2 MASH Trial

By charlie maddox / 11/2025

AASLD The Liver Meeting

NASH, PUBLICATIONS

Denifanstat elicited a significant ≥ 2-stage improvement in fibrosis in F3 MASH patients, and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients: secondary analysis of phase 2b FASCINATE-2 trial

By charlie maddox / 11/2025

AASLD The Liver Meeting

Post pagination

1 2 … 6 Next →

Site map

About
Science
Investors
Programs
Contact

About
Science
Investors
Programs
Contact

Contact us

Business Development
bd@sagimet.com

Investors
ir@sagimet.com

Media
media@sagimet.com

Human Resources
hr@sagimet.com

© 2025 Sagimet Biosciences. All Rights Reserved. Terms of Use Agreement | Privacy Policy | Clinical Trial Privacy Notice

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

Scroll to Top